Most Read Articles
Roshini Claire Anthony, 02 Feb 2018

The use of weight loss medications for at least 1 year did little to improve cardiometabolic risk factors in obese adults, according to a systematic review and meta-analysis.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
26 Feb 2019
Oral fluoxetine confers beneficial effects in the management of adult and adolescent amblyopia, suggests a recent study.
19 Feb 2019
Preprandial administration of metformin successfully and safely reduces postprandial plasma triglyceride levels, a new study has shown.

Antibiotic prophylaxis helps prevent recurrent UTI-related new renal scarring

05 Aug 2019
The increasing shortage of a commonly used antibiotic, Tazocin, has raised concerns on an international scale.

Antibiotic prophylaxis can reduce the risk of new renal scarring associated with recurrent urinary tract infection (UTI), results of the RIVUR* trial have shown.

The authors included 489 patients (mean age, 20.3 months; 91 percent female). Those with recurrent UTI were more likely to have any new renal scarring (odds ratio [OR], 4.1, 95 percent CI, 2.0–8.5; p<0.01) after adjusting for age, sex, index UTI, duplication, bowel bladder dysfunction and antibiotic prophylaxis.

Fewer patients on antibiotic prophylaxis (n=5/244; 2 percent) than on placebo (n=13/245; 5 percent) experienced recurrent UTI-related new renal scarring.

Children on placebo had a higher risk of recurrent UTI-related new renal scarring (OR, 3.1, 1.0–8.8; p=0.04) compared with those on antibiotic prophylaxis after further adjustments for hydronephrosis, vesicoureteral reflux grade and baseline renal scarring.

No between-group differences were observed in scar severity at final dimercaptosuccinic acid scan (p=0.88) or change from baseline (p=0.53).

“It remains unclear why new renal scarring developed in a proportion of [patients] without recurrent urinary tract infection,” the authors said. “The results should be carefully interpreted due to the inherent limitations.”

This study included children with dimercaptosuccinic acid scan within 6 months of enrolment and at least 1 follow-up dimercaptosuccinic acid scan from the RIVUR trial. Recurrent UTI-related new renal scarring, defined as recurrent UTI and new changes on dimercaptosuccinic acid scan, was the primary outcome. Propensity score was used to adjust for confounders due to a low number of events. The associations between covariates and outcome was assessed using multivariate logistic regression.

*Randomized Intervention for Children with Vesicoureteral Reflux

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 02 Feb 2018

The use of weight loss medications for at least 1 year did little to improve cardiometabolic risk factors in obese adults, according to a systematic review and meta-analysis.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
26 Feb 2019
Oral fluoxetine confers beneficial effects in the management of adult and adolescent amblyopia, suggests a recent study.
19 Feb 2019
Preprandial administration of metformin successfully and safely reduces postprandial plasma triglyceride levels, a new study has shown.